Meta-Analysis of COVID-19 Metabolomics Identifies Variations in Robustness of Biomarkers.

ABSTRACT: The global COVID-19 pandemic resulted in widespread harms but also rapid advances in vaccine development, diagnostic testing, and treatment. As the disease moves to endemic status, the need to identify characteristic biomarkers of the disease for diagnostics or therapeutics has lessened, but lessons can still be learned to inform biomarker research in dealing with future pathogens. In this work, we test five sets of research-derived biomarkers against an independent targeted and quantitative Liquid Chromatography-Mass Spectrometry metabolomics dataset to evaluate how robustly these proposed panels would distinguish between COVID-19-positive and negative patients in a hospital setting. We further evaluate a crowdsourced panel comprising the COVID-19 metabolomics biomarkers most commonly men

SUBMITTER: Onoja A 

PROVIDER: S-EPMC10531504 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature